179 related articles for article (PubMed ID: 25658662)
1. Pasireotide (SOM230) prevents sulfonylurea-induced hypoglycemia in rats.
Schmid HA
Exp Clin Endocrinol Diabetes; 2015 Mar; 123(3):193-7. PubMed ID: 25658662
[TBL] [Abstract][Full Text] [Related]
2. Effects of somatostatin analogs on glucose homeostasis in rats.
Schmid HA; Brueggen J
J Endocrinol; 2012 Jan; 212(1):49-60. PubMed ID: 21987782
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Schmid HA; Silva AP
J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
[TBL] [Abstract][Full Text] [Related]
4. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis.
Imhof AK; Glück L; Gajda M; Lupp A; Bräuer R; Schaible HG; Schulz S
Arthritis Rheum; 2011 Aug; 63(8):2352-62. PubMed ID: 21506098
[TBL] [Abstract][Full Text] [Related]
5. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary.
Nolan LA; Schmid HA; Levy A
Endocrinology; 2007 Jun; 148(6):2821-7. PubMed ID: 17347306
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
7. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors.
Streuli J; Harris AG; Cottiny C; Allagnat F; Daly AF; Grouzmann E; Abid K
Neuropeptides; 2018 Apr; 68():84-89. PubMed ID: 29523357
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
[TBL] [Abstract][Full Text] [Related]
9. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
10. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.
Shenouda M; Maldonado M; Wang Y; Bouillaud E; Hudson M; Nesheiwat D; Hu K
Am J Ther; 2014; 21(3):164-73. PubMed ID: 22713526
[TBL] [Abstract][Full Text] [Related]
11. Regulation of ghrelin secretion by somatostatin analogs in rats.
Silva AP; Bethmann K; Raulf F; Schmid HA
Eur J Endocrinol; 2005 Jun; 152(6):887-94. PubMed ID: 15941929
[TBL] [Abstract][Full Text] [Related]
12. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.
van der Hoek J; de Herder WW; Feelders RA; van der Lely AJ; Uitterlinden P; Boerlin V; Bruns C; Poon KW; Lewis I; Weckbecker G; Krahnke T; Hofland LJ; Lamberts SW
J Clin Endocrinol Metab; 2004 Feb; 89(2):638-45. PubMed ID: 14764775
[TBL] [Abstract][Full Text] [Related]
13. Octreotide for sulfonylurea-induced hypoglycemia following overdose.
Carr R; Zed PJ
Ann Pharmacother; 2002 Nov; 36(11):1727-32. PubMed ID: 12398568
[TBL] [Abstract][Full Text] [Related]
14. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure.
Vallurupalli S
Ann Pharmacother; 2010 Feb; 44(2):387-90. PubMed ID: 20118140
[TBL] [Abstract][Full Text] [Related]
15. Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.
Tarasco E; Seebeck P; Pfundstein S; Daly AF; Eugster PJ; Harris AG; Grouzmann E; Lutz TA; Boyle CN
Endocrine; 2017 Oct; 58(1):124-133. PubMed ID: 28822091
[TBL] [Abstract][Full Text] [Related]
16. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses.
Boyle PJ; Justice K; Krentz AJ; Nagy RJ; Schade DS
J Clin Endocrinol Metab; 1993 Mar; 76(3):752-6. PubMed ID: 8445035
[TBL] [Abstract][Full Text] [Related]
17. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia.
Fasano CJ; O'Malley G; Dominici P; Aguilera E; Latta DR
Ann Emerg Med; 2008 Apr; 51(4):400-6. PubMed ID: 17764782
[TBL] [Abstract][Full Text] [Related]
18. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.
Henry RR; Ciaraldi TP; Armstrong D; Burke P; Ligueros-Saylan M; Mudaliar S
J Clin Endocrinol Metab; 2013 Aug; 98(8):3446-53. PubMed ID: 23733372
[TBL] [Abstract][Full Text] [Related]
19. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats.
Silva AP; Schoeffter P; Weckbecker G; Bruns C; Schmid HA
Eur J Endocrinol; 2005 Sep; 153(3):R7-R10. PubMed ID: 16131595
[TBL] [Abstract][Full Text] [Related]
20. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.
Pöll F; Lehmann D; Illing S; Ginj M; Jacobs S; Lupp A; Stumm R; Schulz S
Mol Endocrinol; 2010 Feb; 24(2):436-46. PubMed ID: 20051480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
